Market research
NGM NGM Biopharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 129M
- P/E ratio
- Not available
- Analyst target
- 1.66
- Dividend yield
- Not available
- Beta
- 1.26
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US62921N1054
- Market cap
- 129M
- P/E ratio
- Not available
- Analyst target
- 1.66
- Dividend yield
- Not available
- Beta
- 1.26
About
About NGM Biopharmaceuticals Inc
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NGM discussion.
5 years, 4 months ago
NGM Biopharmaceuticals, Inc is currently in a long term downtrend where the price is trading 11.4% below its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.2.
NGM Biopharmaceuticals, Inc's total revenue sank by 36.4% to $20M since the same quarter in the previous year.
Its net income has dropped by 75.6% to $-28M since the same quarter in the previous year.
Finally, its free cash flow fell by 29.7% to $-20M since the same quarter in the previous year.
Based on the above factors, NGM Biopharmaceuticals, Inc gets an overall score of 1/5.